• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form POS AM filed by Sharps Technology Inc.

    1/29/25 1:25:05 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care
    Get the next $STSS alert in real time by email
    POS AM 1 formposam.htm

     

    Registration No. 333-284237

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    POST EFFECTIVE AMENDMENT NO. 1 TO

    FORM S-1

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

    Sharps Technology, Inc.

    (Exact name of registrant as specified in its charter)

     

    Nevada 3841   82-3751728
    (State or other jurisdiction of   (Primary Standard Industrial   (I.R.S. Employer
    incorporation or organization) Classification Code Number) Identification Number)

     

    Sharps Technology, Inc.

    105 Maxess Road, Ste. 124

    Melville, New York 11747

    (631) 574 -4436

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

    Robert M. Hayes

    Chief Executive Officer

    Sharps Technology, Inc.

    105 Maxess Road, Ste. 124

    Melville, New York 11747

    (631) 574 -4436

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copies to:

     

    Arthur Marcus, Esq.

    Sichenzia Ross Ference LLP

    1185 Avenue of the Americas

    New York, NY 10036

    (212) 930-9700

     

    Anthony W. Basch, Esq.

    J. Britton Williston, Esq.

    Shannon M. McDonough, Esq.

    Kaufman & Canoles

    Two James Center, 14th floor

    Richmond, VA 23219

    Tel: (804) 771-5700

     

    Approximate date of commencement of proposed sale to the public: As soon as practicable after this registration statement becomes effective.

     

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box. ☒

     

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☒

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐   Accelerated filer ☐
    Non-accelerated filer ☒   Smaller reporting company ☒
        Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

    The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant will file a further amendment which specifically states that this registration statement will thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement will become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.

     

    The registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until this Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.

     

     

     

     

     

     

    EXPLANATORY NOTE AND INCORPORATION BY REFERENCE

     

    The purpose of filing this Post-Effective Amendment No. 1 (the “Post-Effective Amendment”) is to provide additional detailed information with respect to the actual shares sold in the offering in Exhibit 107 included herein. There are no additional securities being registered from the Exhibit 107 filed as part of the S-1 MEF filed on January 28, 2025 (File No. 333-284435).

     

    The contents of the earlier registration statement on Form S-1 (File No. 333-284237) initially filed by the Registrant with the Securities and Exchange Commission (the “Commission”) on January 10, 2025, as amended by the Amendment No. 2 filed with the Commission on January 27, 2025 (the “Prior Registration Statement”), which was declared effective by the Commission on January 27, 2025 at 4:30 p.m., and all exhibits thereto are incorporated in this Registration Statement by reference.

     

    The required opinion and consents are listed on an Exhibit Index attached hereto and filed herewith.

     

     

     

     

    PART II

     

    INFORMATION NOT REQUIRED IN PROSPECTUS

     

    Item 16. Exhibits and Financial Statement Schedules.

     

    Exhibits

     

    See the Exhibit Index immediately preceding the signature page hereto for a list of exhibits filed as part of this registration statement on Form S-1, which Exhibit Index is incorporated herein by reference.

     

    Financial Statement Schedules

     

    All financial statement schedules are omitted because the information called for is not required or is shown either in the financial statements or in the notes thereto.

     

     

     

     

    EXHIBIT INDEX

     

    Exhibit    
    Number   Description
    1.1*   Form of Underwriting Agreement, dated [___], 2025, between the Company and Aegis Capital Corp.*
    3.1   Amended and Restated Bylaws*
    3.2   Certificate of Designation of Series A Preferred Stock (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715)
    3.4*   Form of Series A Warrant
    3.5*   Form of Series B Warrant
    3.6   Certificate of Amendment to Designation, filed on December 28, 2022 (incorporated by reference to 8-K filed on December 22, 2022)
    5.1   Legal Opinion of Sichenzia Ross Ference LLP*
    10.1   Asset/Share Purchase Agreement, dated June 10, 2020, among the Company, Safegard Medical (Hungary) Ktf,, Numan Holding Ltd, Cortrus Services SA and Latitude Investments Limited (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715)
    10.2   Amendment No. 1 to Asset/Share Purchase Agreement, dated June 24, 2020 (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715)
    10.3   Amendment No. 2 to Asset/Share Purchase Agreement, dated August 27, 2020 (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715)
    10.4   Amendment No. 3 to Asset/Share Purchase Agreement, dated October 28, 2020 (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715)
    10.5   Amendment No. 4 to Asset/Share Purchase Agreement, dated July 19, 2021 (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715)
    10.6   Amendment No. 5 to Asset/Share Purchase Agreement, dated February 28, 2022 (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715)
    10.7   Letter, dated September 23, 2021, from Numan Holding Ltd (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715)
    10.8   Employment Agreement, dated September 9, 2021, between the Company and Robert Hayes (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715)
    10.9   Consulting Agreement between the Company and Alan Blackman (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715)
    10.10   Amended Consulting Agreement, dated May 28, 2019, between the Company and Barry Berler (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715)
    10.11   Royalty Agreement, dated July 11, 2017, between Alan Blackman and Barry Berler (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715)
    10.12   Amendment to Royalty Agreement, dated September 4, 2018 (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715)
    10.13   Consulting Agreement, dated January 1, 2021, between the Company and Berry Berler (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715)
    10.14   Note Purchase Agreement, dated December 14, 2021, among the Company and the purchasers named therein (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715)
    10.15   Form of Note (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715)
    10.16   Security Agreement among the Company and the secured parties named therein (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715)
    10.17   Consent to be named as a director nominee of Jason Monroe (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715)
    10.18   Consent to be named as a director nominee of Brenda Baird Simpson (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715)
    10.22   2022 Equity Incentive Plan (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715)
    10.23   Plan and Agreement of Merger, dated March 22, 2022, between Sharps Technology, Inc., a Wyoming corporation, and Sharps Technology, Inc., a Nevada corporation (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333- 263715)
    10.24   Form of Warrant Agent Agreement (Warrants) (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715)
    10.25   Form of Representative’s Warrant (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715)
    10.26   Amendment No. 6 to Asset/Share Purchase Agreement, dated April 13, 2022 (incorporated by reference to 8-K filed on April 19, 2022)
    10.27   Agreement, dated September 29, 2022, by and among Sharps Technology, Inc., InjectEZ, LLC, Nephron Pharmaceuticals Corporation, Nephron SC, Inc. and Nephron Sterile Compounding Center LLC (incorporated by reference to 8-K filed on October 4, 2022)
    10.28   Distribution Agreement, dated December 8, 2022, by and among Sharps Technology, Inc., Nephron Pharmaceuticals Corporation and Nephron SC, Inc. (incorporated by reference to 8-K filed on December 13, 2022)
    10.29   PIPE Agreement, dated September 27, 2023 (incorporated by reference to 8-K filed on October 3, 2023) Rd Agreement, dated September 27, 2023 (incorporated by reference to 8-K filed on October 3, 2023)
    10.30   Registration Rights Agreement, dated September 27, 2023 (incorporated by reference to 8-K filed on October 3, 2023)
    10.31   Placement Agent Agreement, dated September 27, 2023 (incorporated by reference to 8-K filed on October 3, 2023)
    10.32   Form of Warrant (incorporated by reference to 8-K filed on October 3, 2023)
    10.33   Form of RD Pre-Funded Warrant (incorporated by reference to 8-K filed on October 3, 2023)
    10.34   Form of PIPE Pre-Funded Warrant (incorporated by reference to 8-K filed on October 3, 2023)
    10.35   2023 Equity Incentive Plan (incorporated by reference to 8-K filed on January 27, 2023)
    10.36   2024 Equity Incentive Plan*
    23.1   Consent of Manning Elliott LLP*
    23.2   Consent of PKF O’Conner Davies, LLP*
    23.3   Consent of Sichenzia Ross Ference LLP (included in Exhibit 5.1)*
    24.1   Power of Attorney*
    107   Filing Fees Exhibit

     

    * Previously Filed

     

    II-2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement on Form S-1 to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Melville, State of New York, on the 29th day of January, 2025.

     

    SHARPS TECHNOLOGY, INC  
         
    By: /s/ Robert M. Hayes  
      Robert M. Hayes  
      Chief Executive Officer and Director  

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Robert M. Hayes, as his true and lawful attorney-in-fact and agent with full power of substitution, for him in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments or any abbreviated registration statement and any amendments thereto filed pursuant to Rule 462(b) increasing the number of securities for which registration is sought), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact, proxy and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact, proxy and agent, or his substitute, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement on Form S-1 has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Robert M. Hayes   Chief Executive Officer and Director   January 29, 2025
    Robert M. Hayes   (Principal Executive Officer)    
             
    /s/ Andrew R. Crescenzo   Chief Financial Officer   January 29, 2025
    Andrew R. Crescenzo   (Principal Financial and Accounting Officer)    
             
    /s/ Dr. Soren Bo Christiansen*   Chairman   January 29, 2025
    Dr Soren Bo Christiansen        
             
    /s/ Paul K. Danner*   Director   January 29, 2025
    Paul K. Danner        
             
    /s/ Timothy J. Ruemler*   Director   January 29, 2025
    Timothy J. Ruemler        
             
    /s/ Brenda Baird Simpson*   Director   January 29, 2025
    Brenda Baird Simpson        
             
    /s/ Jason L Monroe*   Director   January 29, 2025
    Jason L Monroe        
             
    * By: /s/ Robert M. Hayes       January 29, 2025
    Robert M. Hayes        
    Attorney-in-fact        

     

    II-3

     

    Get the next $STSS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $STSS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $STSS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sharps Technology Expands Digital Asset Treasury Strategy with Coinbase

    NEW YORK, Oct. 9, 2025 /PRNewswire/ -- Sharps Technology, Inc. ("STSS" or the "Company") (NASDAQ:STSS) and Coinbase Global, Inc ("Coinbase"), one of the world's largest digital asset services platforms, today announced a strategic collaboration whereby STSS will expand its previously announced Solana digital asset treasury strategy with Coinbase. STSS has acquired over 2 million SOL to-date, which are currently valued at over $400 million with SOL trading at over $210. "Coinbase is an ideal platform for STSS as it seeks to leverage its digital asset treasury strategy to help a

    10/9/25 7:00:00 AM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Sharps Technology Announces $100 Million Stock Repurchase Program

    NEW YORK, Oct. 2, 2025 /PRNewswire/ -- Sharps Technology, Inc. ("STSS" or the "Company") (NASDAQ:STSS) today announced a stock repurchase program to acquire up to $100 million of the company's outstanding common stock. This new stock repurchase program will enable the company to repurchase its shares in the open market and in negotiated transactions. STSS previously announced its plans to establish a Solana digital asset treasury strategy and has acquired over 2 million SOL thus far. Forward Looking Statements This press release contains "forward-looking statements" within the

    10/2/25 7:00:00 AM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Crypto.com and Sharps Technology Partner to Strengthen Solana Ecosystem Growth Through Institutional Treasury Solutions

    NEW YORK, Sept. 29, 2025 /PRNewswire/ -- Crypto.com and Sharps Technology, Inc. (the "Company" or "STSS") (Nasdaq: "STSS" and "STSSW") today announced that STSS has expanded its digital asset treasury strategy with Crypto.com services for its holdings. STSS is an emerging leader in digital asset treasury management, with a bold vision to align traditional finance with the Solana ecosystem. The Company has previously announced plans to establish a Solana-focused digital asset treasury strategy and, to date has acquired more than 2 million SOL. As part of this collaboration, STS

    9/29/25 7:00:00 AM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    $STSS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ruemler Timothy James increased direct ownership by 294% to 40,218 units (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    8/26/25 9:45:47 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Crescenzo Andrew R. bought $256,400 worth of Option (40,000 units at $6.41) (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    8/26/25 9:24:34 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Director Monroe Jason L. bought $512,800 worth of Option (80,000 units at $6.41) (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    8/26/25 9:24:36 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    $STSS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sharps Technology Inc.

    SC 13G/A - Sharps Technology Inc. (0001737995) (Subject)

    11/13/24 4:50:17 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sharps Technology Inc.

    SC 13G/A - Sharps Technology Inc. (0001737995) (Subject)

    10/9/24 9:01:14 AM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Sharps Technology Inc.

    SC 13G - Sharps Technology Inc. (0001737995) (Subject)

    2/14/24 11:14:11 AM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    $STSS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Investment Officer Zhang Yuwen

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    10/6/25 4:32:03 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    New insider Zhang Yuwen claimed ownership of 14,040 shares (SEC Form 3)

    3 - Sharps Technology Inc. (0001737995) (Issuer)

    10/6/25 4:30:25 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Director Ruemler Timothy James sold $334,786 worth of shares (20,000 units at $16.74), decreasing direct ownership by 50% to 20,218 units (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    8/28/25 9:21:49 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    $STSS
    SEC Filings

    View All

    SEC Form D filed by Sharps Technology Inc.

    D - Sharps Technology Inc. (0001737995) (Filer)

    10/31/25 3:11:17 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    SEC Form S-3 filed by Sharps Technology Inc.

    S-3 - Sharps Technology Inc. (0001737995) (Filer)

    10/23/25 4:31:08 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Sharps Technology Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Sharps Technology Inc. (0001737995) (Filer)

    10/15/25 4:20:42 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    $STSS
    Leadership Updates

    Live Leadership Updates

    View All

    Sharps Technology Planning To Collaborate With Roncadelle To Support Global Distribution And Sales Of High Quality, Innovative, Safer Drug Delivery Systems

    NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ:STSS) (NASDAQ:STSSW), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, is working to create new sales and distribution opportunities through the addition of new North American 3PL partnerships to expand its reach into the global healthcare market. These additional third-party logistics partnerships, along with a developing alliance with Roncadelle Operations, a driving force in the development of safe, novel medical drug delivery devices, would combine the strengths and capabilities of the two companies to develop, market and distribute unique dru

    2/16/24 2:42:54 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Sharps Technology Appoints Industry Sales and Manufacturing Leader Ben Scheu as Senior Director of Sales

    Key appointment with demonstrated experience in leading sales and marketing operations to oversee commercial initiatives as the Company launches its specialty smart safety syringe products to the market Product qualification and sales initiatives underway as company prepares for U.S. commercial operations NEW YORK, July 12, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the "Company") (NASDAQ: "STSS" and "STSSW"), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, is pleased to announce the appointment of Ben Scheu as Senior Director of Sales to lead commercial operations as the Company prepares to launch products to the market.

    7/12/23 8:33:00 AM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Sharps Technology Appoints Justin Page as Vice President of Technical Operations

    NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the "Company", "Sharps") (NASDAQ: "STSS" and "STSSW"), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, appoints Justin Page as Vice President of Technical Operations. In his role, Mr. Page will be responsible for managing all aspects of Sharps' engineering operations. His primary focus will be to provide the leadership and technical expertise to support the prefillable syringe collaboration with Nephron Pharmaceuticals at the InjectEZ facility. These efforts will include the support for the injection molding of the specialty components and the high speed assembl

    2/9/23 9:21:23 AM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    $STSS
    Financials

    Live finance-specific insights

    View All

    Sharps Technology, Inc. Acquires Over 2 Million SOL, the Native Asset of Solana, the Fastest and Most Used Public Blockchain

    NEW YORK, Sept. 2, 2025 /PRNewswire/ -- Sharps Technology, Inc. (the "Company" or "Sharps Technology") (Nasdaq: "STSS" and "STSSW") today announced its first acquisition of Solana ("SOL") tokens as part of its digital asset treasury strategy under which the principal holding will be SOL, the native digital asset of the Solana blockchain. Funded from the Company's recent PIPE equity raise, Sharps Technology now holds over 2 million SOL, creating a SOL treasury currently valued north of $400M. Sharps Technology intends to provide regular updates on its SOL holdings and performan

    9/2/25 7:00:00 AM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Soligenix and Sharps Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

    ORLANDO, FL / ACCESSWIRE / June 7, 2024 / RedChip Companies will air interviews with Soligenix, Inc. (NASDAQ:SNGX) and Sharps Technology Inc. (NASDAQ:STSS) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, June 8, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Soligenix: https://www.redchip.com/assets/access/sngx_accessSharps Technology: https://www.redchip.com/assets/access/stss_accessIn an exclusive interview, Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix, appears on the RedChip Small Stocks Big Money™ show on B

    6/7/24 9:00:00 AM ET
    $SNGX
    $STSS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Sharps Technology, Reviva Pharmaceuticals, and American Resources Corp. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

    ORLANDO, FL / ACCESSWIRE / September 29, 2023 / RedChip Companies will air interviews with Sharps Technology, Inc. (NASDAQ:STSS), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and American Resources Corp. (NASDAQ:AREC) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 30, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Sharps Technology: https://www.redchip.com/assets/access/stss_accessReviva Pharmaceuticals: https://www.redchip.com/assets/access/rvph_accessAmerican Resources Corp: https://www.redchip.com/assets/access/arec_accessAbout The RedChip

    9/29/23 9:00:00 AM ET
    $AREC
    $RVPH
    $STSS
    Coal Mining
    Energy
    Biotechnology: Pharmaceutical Preparations
    Health Care